Remgro Limited (DE:RE7)
FRANKFURT:RE7
Earnings Data
Report Date
Sep 17, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
―Last Year’s EPS
-0.03Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a clearly positive financial and strategic momentum for Remgro: materially stronger headline earnings, materially higher dividends and cash generation, successful completion of key corporate actions (CIVH/Vodacom, BAT sale, FirstRand monetizations) and operational turnarounds at several investees (Mediclinic, CIVH, Rainbow, Heineken Beverages). That said, management flagged meaningful near-term and sector-specific risks — notably RCL Foods’ sugar weakness and industry stress, volatility in Mediclinic’s Middle East operations from geopolitical conflict, valuation sensitives and some modest INAV growth versus earnings. Overall the tone was constructive and confident about execution but realistic about macro and specific operational headwinds.Company Guidance
Strong headline earnings growth
Headline earnings rose ~38.8% to ZAR 5.2 billion (6 months ended 31 Dec 2025) with headline earnings per share up ~38.5% from ZAR 6.72 to ZAR 9.31, reflecting broad-based portfolio earnings momentum.
Material uplift in dividends and cash generation
Sustainable ordinary dividends received at the center increased ~34% to ZAR 2.4 billion (versus ZAR 1.8 billion prior period). Interim ordinary dividend increased ~80.2% to ZAR 1.73 per share (from ZAR 0.96). Net cash at center rose by ZAR 3.7 billion to ZAR 12 billion and total liquidity was ~ZAR 19 billion.
Notable portfolio re‑shaping and monetizations
Successfully completed CIVH/Vodacom transaction (including a Remgro share of the Maziv pre-implementation dividend of ZAR 2.66 billion), sold remaining BAT stake for net ZAR 1.1 billion, distributed/monetized media assets (eMedia unbundling ~ZAR 0.75 per share impact) and monetized part of FirstRand (proceeds after CGT reported; further disposals since Dec produced ~ZAR 4.0 billion after CGT).
Mediclinic delivered robust operating performance
Mediclinic revenue +10% to $2.6bn (5% in constant currency), adjusted EBITDA +23% to $397m (18% cc), adjusted earnings +91% to $159m; Southern Africa revenue +8% to ZAR 12bn and adjusted EBITDA +12% to ZAR 2.2bn. Cash conversion improving (84% YTD with target 90–100% by year-end).
Breakthrough profitability and strong momentum at CIVH / Maziv / Vumatel
CIVH moved to sustained profitability (CIVH contribution to Remgro headline earnings converted from a prior loss to profit; CIVH reported operating revenue growth and free-cash-flow improvements: free cash flow before CapEx increased ~31% to ZAR 1.5 billion). CIVH valuation (ex dividend) increased modestly (ZAR 15.8bn → ZAR 16.2bn) and like-for-like including the pre-implementation dividend shows ~19.6% uplift.
Strong consumer products turnaround contributors
Rainbow delivered a substantial turnaround: contribution increased ~110% to ZAR 535 million. Heineken Beverages showed revenue growth (c.2%) and earnings/margins expansion with a strong turnaround from a low base; HeinBev valuation +~12% and delivered ZAR 155m profit vs prior loss.
Industrial and financial investments performing
OUTsurance contribution +14.3% to ZAR 713 million. Air Products contribution +11.4% to ZAR 380 million. TotalEnergies contribution increased >100% (largely due to a one-off transit pipeline cost refund; Remgro share ZAR 218m).
INAV and valuation discipline
INAV per share increased modestly by 1.6% from ZAR 292.34 to ZAR 297.30 (3.4% increase adjusted for distributions). Remgro emphasised conservative, consistent valuation methodology (DCF primary with calibrated multiples) and moderated terminal assumptions despite lower discount rates.
Progress on corporate simplification and strategic restructurings
Mediclinic restructuring in-principle agreement reached to realign regional ownership (Remgro to own 100% of Mediclinic Southern Africa) to simplify the group; progress on Herotel second leg pending CASA approval; active consideration of capital allocation options including possible share buybacks (under active assessment).
DE:RE7 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:RE7 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 25, 2026 | €8.95 | €9.35 | +4.47% |
Sep 23, 2025 | €8.08 | €8.03 | -0.52% |
Mar 25, 2025 | €7.45 | €7.49 | +0.64% |
Sep 19, 2024 | €7.07 | €7.02 | -0.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Remgro Limited (DE:RE7) report earnings?
Remgro Limited (DE:RE7) is schdueled to report earning on Sep 17, 2026, Before Open (Confirmed).
What is Remgro Limited (DE:RE7) earnings time?
Remgro Limited (DE:RE7) earnings time is at Sep 17, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Remgro Limited stock?
The P/E ratio of Remgro is N/A.
What is DE:RE7 EPS forecast?
Currently, no data Available